MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Lee Hodge, MBA, senior associate scientist, Strategic Consulting Services, has been invited to speak to drug development scientists and operations research professionals attending the Institute for Operations Research and the Management Sciences (INFORMS) Annual Meeting, to be held in Seattle, Washington at the Washington State Convention and Trade Center from November 4-7, 2007.
Mr. Hodge will present a case study illustrating the strategic benefits of linking quantitative drug-disease modeling and decision analysis to assess the clinical and commercial potential of a drug development program. Mr. Hodge’s presentation, entitled “Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation”, will take place on November 6, 2007 at 4:30 pm. Mr. Hodge’s talk will describe the process by which an integrated metric of net patient benefit, the clinical utility index (CUI), was developed and combined with predictive pharmacostatistical models to assess multiple product tradeoffs and support a “go/no-go” investment decision for a new drug formulation. The conference will also provide a forum for scientific discussion and collaborative exchange on the application of decision analysis methods to evaluate new medical treatments. Additional information can be found at http://meetings.informs.org/Seattle07/index.html.
“Model-based drug development, which is advocated by the Food and Drug Administration in its Critical Path initiative, goes well beyond PK/PD modeling to support dosing choices,” said Shawn O’Connor, president, CEO, and chairman of Pharsight. “This presentation demonstrates how development of a CUI integrates scientific and commercial considerations for assessing net patient benefit, and offers a powerful set of approaches to help navigate the inherent complexity and uncertainty in clinical drug development. Decision scientists and modeling experts in Pharsight’s Strategic Consulting Services group are uniquely positioned to build a CUI and to link it with quantitative models of drug action and effect to help our pharmaceutical and biotechnology industry clients make more confident decisions and deliver stronger commercial results. We look forward to participating at the INFORMS annual meeting, and to exchanging information with industry colleagues on the strategic use of modeling and simulation.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.
CONTACT: Investors, Douglas Sherk, +1-415-896-6820, or Jennifer
Beugelmans, +1-646-201-5447, or media, Jen Saunders, +1-646-201-5431, all
of EVC Group for Pharsight Corporation
Web site: http://www.pharsight.com/
